Nosa Plugs (NOSA) Investor Update summary

Strategic acquisition and rationale

• Agreement signed to acquire all shares in Pharmacure Health Care International AB for approximately 27.2 MSEK on a cash- and debt-free basis, aligning with the strategy to expand in nasal health.

• Acquisition expected to broaden the product portfolio, strengthen market position, and create opportunities for cost and revenue synergies.

• Nozoil, Pharmacure’s main product, is the world’s best-selling emollient nasal spray, with 2024 sales of about 12.8 MSEK and a positive adjusted net result.

• Nozoil’s sales are concentrated in markets where the acquirer currently lacks presence, offering new growth opportunities.

• The deal supports the ambition to become a leading, profitable group in nasal health and is expected to generate significant shareholder value.

Transaction structure and financial impact

• 47.5% of the purchase price will be paid at closing, with the remainder over 27 months; part of the payment will be in new shares.

• Seller commits to a 12-month lock-up period for shares received.

• The acquisition is expected to pay for itself within three years and will be consolidated into group accounts upon completion.

• The transaction is subject to financing and regulatory approval, including FDI clearance.

• The acquisition is anticipated to have a positive impact on EBITA over time.

Integration and operational outlook

• Nozoil will be launched through the acquirer’s global distribution network and supported by its sales force and pharmacy presence.

• Pharmacure’s other nasal and cosmetic products are excluded from the deal and will be separated before closing.

• Pharmacure’s owner will remain involved as a consultant post-transaction.

• Focus remains on core business with strong organic growth, while the acquisition accelerates expansion in the ENT segment.

• Completion is expected by Q3 2025, pending fulfillment of all conditions.